Tirzepatide vs survodutide: evidence, cost, and legality

Which is better, tirzepatide or survodutide?

No trial has compared them directly, but tirzepatide's placebo-controlled weight loss is larger, it is approved for weight management, sleep apnea, and type 2 diabetes, and SURPASS-CVOT showed cardiovascular protection comparable to dulaglutide. Survodutide is not approved anywhere and is only available in trials. [1] [2] [3] [4] [5]

How do tirzepatide and survodutide compare?

Tirzepatide and Survodutide compared by dimension
Dimension	TirzepatideFavored	Survodutide
Mechanism [2] [4]	Dual GIP and GLP-1 receptor agonist.	Dual glucagon and GLP-1 receptor agonist.
Note: Both are dual agonists, but the second receptor differs: GIP for tirzepatide, glucagon for survodutide.
Pivotal weight loss [1] [2]	15.0%, 19.5%, and 20.9% at 5, 10, and 15 mg versus 3.1% on placebo at 72 weeks (SURMOUNT-1, 2,539 adults).	12.2% (3.6 mg) and 13.0% (6.0 mg) versus 5.4% on placebo at 76 weeks (SYNCHRONIZE-1, 725 adults).
Note: Cross-trial comparison; the trials used different estimands and populations.
Cardiovascular outcomes [2] [3]	SURPASS-CVOT: noninferior to dulaglutide for cardiovascular death, heart attack, or stroke (12.2% versus 13.1%, hazard ratio 0.92) in 13,165 analyzed adults with type 2 diabetes and heart disease.	No cardiovascular outcomes trial has reported.
Liver disease evidence [4] [6]	No MASH indication on the label.	Phase 2 MASH trial: improvement without worsening fibrosis in 47% to 62% versus 14% on placebo at 48 weeks.
Tolerability [1] [2]	Nausea up to 31% at 15 mg versus 10% on placebo in SURMOUNT-1.	Gastrointestinal symptoms in 80.9% to 89.7% versus 47.9% on placebo in SYNCHRONIZE-1, mostly mild to moderate.
Regulatory status [4] [5] [7]	FDA approved (Mounjaro 2022, Zepbound 2023). Shortage-based compounding ended in early 2025.	Investigational; not approved by any regulator and not eligible for compounding.
WADA status [8]	Not on the WADA Prohibited List.	Prohibited under section S0.
Cost and access [5] [9]	Prescription only. Manufacturer self-pay for the KwikPen starts at 299 USD per 28 days at 2.5 mg, and a commercial savings card can bring a covered fill to 25 USD (checked 2026-09-22).	No lawful purchase channel; available only in registered clinical trials. Products sold as research chemicals are not lawful for human use.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Tirzepatide and Survodutide: grade, status, and cost
Attribute	Tirzepatide	Survodutide
Class	Dual GIP and GLP-1 receptor agonist (39 amino acid peptide, acylated for once weekly dosing)	Investigational dual agonist of the glucagon and GLP-1 receptors (acylated peptide, once weekly)
What it is	FDA approved weekly GIP and GLP-1 drug with 20.9% average weight loss at 15 mg in a 72 week randomized trial; beat semaglutide head to head.	Investigational glucagon/GLP-1 dual agonist: 13% weight loss at 76 weeks in phase 3 and strong liver (MASH) data, but not FDA approved.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: Not eligible for compounding
Compounding	FDA approved products (Mounjaro May 2022, Zepbound November 2023). FDA declared the tirzepatide shortage resolved on December 19, 2024; compounding by 503A pharmacies had to stop by February 18, 2025 and by 503B outsourcing facilities by March 19, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit tirzepatide products. On April 30, 2026 FDA proposed not to include tirzepatide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms.	Not FDA approved and not approved by any other regulator as of the last verification date. Because survodutide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded by 503A pharmacies or 503B outsourcing facilities. Any product sold as survodutide outside a clinical trial is an unapproved drug that has not been evaluated for identity, purity, or dose.
WADA	WADA: Not WADA prohibited	WADA: WADA prohibited
Routes	Subcutaneous injection once weekly (pen or single dose vial)	Subcutaneous injection once weekly (clinical trials only)
Typical cost	Manufacturer list price is up to 1,086.37 USD per fill for Zepbound and 1,112.16 USD for Mounjaro (checked 2026-09-22). Manufacturer self-pay Zepbound vials and KwikPen cost 299 USD per month at 2.5 mg, 399 at 5 mg, 499 at 7.5 mg, and 699 at 10 mg and above, with a 449 USD on-time refill offer for the 7.5 mg and higher KwikPen through 2026. With commercial insurance a savings card can bring a covered prescription to 25 USD, and eligible Medicare Part D enrollees pay 50 USD per month for the Zepbound KwikPen under the Medicare GLP-1 Bridge (July 2026 to December 2027). A study published in 2025 found compounded tirzepatide advertised at a median 330 USD for the first month during the shortage; compounding is now limited to patient specific needs.	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 27, 2026	Sep 27, 2026

Has tirzepatide been tested directly against survodutide?

No published trial has compared tirzepatide and survodutide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do tirzepatide and survodutide cost?

Typical cost of Tirzepatide and Survodutide
Dimension	Tirzepatide	Survodutide
Typical cost	$275 to $1,112 per month	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	Tirzepatide price by channel	Price index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Which causes more weight loss, tirzepatide or survodutide?

Tirzepatide, based on separate trials: up to 20.9% at 72 weeks in SURMOUNT-1 versus 12.2% to 13.0% at 76 weeks for survodutide in SYNCHRONIZE-1. They have not been tested head to head. [1] [2]

Is survodutide better for the liver?

Its liver data are its strongest point: in a phase 2 MASH trial up to 62% improved versus 14% on placebo. Tirzepatide has no MASH indication, but survodutide is not approved for any use. [4] [6]

Can survodutide be compounded like tirzepatide was?

No. Tirzepatide could be compounded only while it was in shortage, which ended in December 2024. Survodutide was never approved, is not on the 503A bulks list, and cannot lawfully be compounded at all. [5] [7]

Is either one banned in sport?

Survodutide is prohibited under WADA section S0 as a non-approved substance. Tirzepatide is not on the list. [8]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Tirzepatide vs survodutide: evidence, cost, and legality. https://peptideagent.ai/compare/tirzepatide-vs-survodutide
HTML link: <a href="https://peptideagent.ai/compare/tirzepatide-vs-survodutide">Tirzepatide vs survodutide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Tirzepatide vs survodutide

The short answer